Vital Therapies is a biotherapeutic company developing a cell-based system for the treatment of acute forms of liver failure. The Company’s lead product candidate, the ELAD® System, is a human cell-based, bio-artificial liver support system currently in Phase III clinical trials. 

ELAD is an investigational extracorporeal liver support system designed with the proposed intent to supplement hepatic function in order to improve survival rates among subjects with liver failure. Data from ELAD system clinical studies have shown trends that may indicate a potential for ELAD to increase survival rates in patients with liver failure.

Type
Public
HQ
San Diego, US
Founded
2003
Size (employees)
87 (est)
Vital Therapies was founded in 2003 and is headquartered in San Diego, US
Report incorrect company information

Vital Therapies Office Locations

Vital Therapies has an office in San Diego
San Diego, US (HQ)
15010 Avenue of Science
Show all (1)
Report incorrect company information

Vital Therapies Financials and Metrics

Vital Therapies Financials

USD

Net income (Q1, 2018)

(14.4 m)

EBIT (Q1, 2018)

(14.5 m)

Market capitalization (14-Jun-2018)

245.7 m

Closing share price (14-Jun-2018)

5.8

Cash (31-Mar-2018)

43.6 m
Vital Therapies's current market capitalization is $245.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

10.9 m12.3 m11.2 m13.3 m

R&D expense

39.5 m39.8 m30 m39.3 m

Operating expense total

50.3 m52.1 m41.3 m52.7 m

EBIT

(50.3 m)(52.1 m)(41.3 m)(52.7 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

General and administrative expense

2.7 m2.5 m2.6 m3.1 m3.5 m2.7 m2.8 m2.7 m2.8 m3.1 m2.7 m3 m4.3 m

R&D expense

9.2 m9.1 m10.2 m11.8 m11.5 m9.6 m6.9 m6.9 m7.5 m9.6 m9.8 m9.7 m10.2 m

Operating expense total

11.9 m11.6 m12.8 m14.8 m15.1 m12.3 m9.7 m9.5 m10.2 m12.7 m12.5 m12.6 m14.5 m

EBIT

(11.9 m)(11.6 m)(12.8 m)(14.8 m)(15.1 m)(12.3 m)(9.7 m)(9.5 m)(10.2 m)(12.7 m)(12.5 m)(12.6 m)(14.5 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

102.2 m83.4 m60 m56.9 m

Inventories

1.3 m30.2 m20.8 m

Current Assets

104.8 m85.1 m61.5 m58.1 m

PP&E

3.1 m3.8 m2.5 m2.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

46 m90.8 m79.1 m88.3 m71.9 m59.8 m77.9 m73.6 m68.1 m86.6 m76.2 m66.4 m43.6 m

Current Assets

52.3 m93.5 m82.6 m90.6 m75.4 m62.6 m79.2 m75.4 m69.5 m88.3 m78.1 m68 m44.8 m

PP&E

3.1 m3.3 m3 m4.1 m4.2 m4.2 m3.4 m3 m2.9 m2.5 m2.4 m2.3 m2.1 m

Total Assets

55.6 m97 m85.8 m94.9 m79.9 m66.9 m82.9 m78.6 m72.5 m90.9 m80.7 m70.4 m47 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.7 m)(52 m)(41 m)(52.1 m)

Depreciation and Amortization

1.1 m1.3 m1.8 m998 k

Inventories

(6.5 m)

Accounts Payable

46 k281 k(459 k)287 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(10.7 m)(10.2 m)(12.8 m)(14.8 m)(15.1 m)(12.3 m)(9.6 m)(9.5 m)(10.2 m)(12.6 m)(14.4 m)

Depreciation and Amortization

224 k

Accounts Payable

1.5 m696 k1.1 m920 k549 k885 k887 k1.2 m1.3 m(145 k)

Cash From Operating Activities

(13.1 m)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information